user

NO DIFFERENCE IN EFFECTIVENESS WITH EITHER ETANERCEPT ORIGINATOR OR BIOSIMILAR AS FIRST LINE BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS

被引：0
|
作者：
De Cock, D. [1 ]
Davies, R. [1 ]
Kearsley-Fleet, L. [1 ]
Watson, K. [1 ]
Hyrich, K. [1 ,2 ]
机构：
[1] Univ Manchester, Arthrit Res UK Ctr Epidemiol, Manchester, Lancs, England
[2] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4508
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0429
引用
收藏
页码：1377 / 1378
页数：3
相关论文
共 50 条
  • [41] ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy
    Santoleri, Fiorenzo
    Lasala, Ruggero
    Abrate, Paolo
    Pestrin, Laura
    Pasut, Enrico
    Modesti, Germana
    Musicco, Felice
    Fulgenzio, Chiara
    Zuzolo, Eva
    Pieri, Gabriella
    Roperti, Martina
    Gazzola, Pietro
    Gambera, Marco
    Martignoni, Isabella
    Montresor, Valentina
    De Vita, Francesco
    Guarino, Francesca
    Grossi, Laura
    Di Fabio, Letizia
    Roberti, Cristina
    Spoltore, Concetta
    Tinari, Gabriella
    De Rosa, Stefania
    Giannini, Romina
    Langella, Roberto
    Mingolla, Grazia
    Piccoli, Mariantonietta
    Costantini, Alberto
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (12) : 1729 - 1735
  • [42] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
  • [43] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN PORTUGAL
    Mateus, C.
    Moura, A.
    VALUE IN HEALTH, 2014, 17 (07) : A380 - A381
  • [44] TOCIUZUMAB EFFECTIVENESS AS FIRST LINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Jarpa, E.
    Jara, C.
    Vergara, C.
    Jurado, M.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S39 - S39
  • [45] Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
    Deakin, Claire
    Littlejohn, Geoffrey
    Griffiths, Hedley
    Smith, Tegan
    OSullivan, Catherine
    Bird, Paul
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1738 - 1740
  • [46] Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis
    Melville, Andrew R.
    Yusof, Md Yuzaiful Md
    Fitton, John
    Garcia-Montoya, Leticia
    Bailey, Lynda
    Dass, Shouvik
    Emery, Paul
    Buch, Maya H.
    Saleem, Benazir
    RHEUMATOLOGY, 2021, 60 (08) : 3679 - 3688
  • [47] Etanercept (Enbrel) - Biologic response modifier to treat rheumatoid arthritis
    不详
    AMERICAN JOURNAL OF NURSING, 1999, 99 (02) : 60 - 60
  • [48] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUS AS FIRST LINE BIOLOGIC MONOTHERAPY FOR RHEUMATOID ARTHRITIS MANAGEMENT IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A671 - A671
  • [49] Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
    Narvaez, Javier
    Diaz-Torne, Cesar
    Magallares, Berta
    Victoria Hernandez, Maria
    Reina, Delia
    Corominas, Hector
    Sanmart, Raimon
    Rodriguez de la Serna, Arturo
    Maria Llobet, Josep
    Nolla, Joan M.
    PLOS ONE, 2015, 10 (04):
  • [50] Cost effectiveness analysis of etanercept versus infliximab in the treatment of rheumatoid arthritis patients
    Malone, DC
    Ortmeier, BG
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 353 - 353
12345